{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:13:42Z","timestamp":1787508822465,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.dld.2016.09.001","type":"journal-article","created":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T16:01:47Z","timestamp":1473868907000},"page":"11-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis"],"prefix":"10.1016","volume":"49","author":[{"given":"Anne-Claire","family":"Frin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Boschetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Flourie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyne","family":"Drai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Hebuterne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Nancey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2016.09.001_bib0165","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2016.09.001_bib0170","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/apt.12289","article-title":"Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience","volume":"37","author":"Laharie","year":"2013","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.dld.2016.09.001_bib0175","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/ibd.20986","article-title":"Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes","volume":"15","author":"Schoepfer","year":"2009","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2016.09.001_bib0180","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1002\/ibd.22917","article-title":"Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease","volume":"18","author":"D\u2019Haens","year":"2012","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2016.09.001_bib0185","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3748\/wjg.14.53","article-title":"Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis","volume":"14","author":"Xiang","year":"2008","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2016.09.001_bib0190","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/00365520410007971","article-title":"Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease","volume":"39","author":"Roseth","year":"2004","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2016.09.001_bib0195","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/1756-0500-2-221","article-title":"Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes","volume":"2","author":"Vieira","year":"2009","journal-title":"BMC Research Notes"},{"key":"10.1016\/j.dld.2016.09.001_bib0200","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1572-0241.2007.01556.x","article-title":"Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices","volume":"103","author":"Langhorst","year":"2008","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2016.09.001_bib0205","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MIB.0b013e3182810066","article-title":"Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger index, C-reactive protein, platelets, hemoglobin, and blood leukocytes","volume":"19","author":"Schoepfer","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2016.09.001_bib0210","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.3748\/wjg.v17.i47.5166","article-title":"Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels","volume":"17","author":"H\u00e4m\u00e4l\u00e4inen","year":"2011","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2016.09.001_bib0215","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.crohns.2011.11.002","article-title":"Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF na\u00efve patients with ulcerative colitis","volume":"6","author":"De Vos","year":"2012","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1016\/j.dld.2016.09.001_bib0220","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1002\/ibd.22863","article-title":"Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF\u03b1 blocking agents","volume":"18","author":"Molander","year":"2012","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2016.09.001_bib0225","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1097\/MIB.0b013e31829b2a37","article-title":"Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy","volume":"19","author":"De Vos","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2016.09.001_bib0230","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.trsl.2012.01.001","article-title":"Biomarkers in inflammatory bowel disease: current practices and recent advances","volume":"159","author":"Iskandar","year":"2012","journal-title":"Translational Research"},{"key":"10.1016\/j.dld.2016.09.001_bib0235","first-page":"5151","article-title":"Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastrointestinal cancer","volume":"20","author":"Hardt","year":"2000","journal-title":"Anticancer Research"},{"key":"10.1016\/j.dld.2016.09.001_bib0240","first-page":"389","article-title":"Comparison of a novel fecal marker, fecal tumor pyruvate kinase type M2 (M2-PK) with fecal calprotectin in patients with inflammatory bowel disease: a prospective study","volume":"54","author":"Shastri","year":"2008","journal-title":"Clinica y Laboratorio"},{"key":"10.1016\/j.dld.2016.09.001_bib0245","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1002\/ibd.20946","article-title":"Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders","volume":"15","author":"Jeffery","year":"2009","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2016.09.001_bib0250","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/gut.2010.211755","article-title":"Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response","volume":"59","author":"Turner","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.dld.2016.09.001_bib0255","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/MCG.0b013e3182582cdb","article-title":"Neopterin concentration as an index of disease activity in Crohn's disease and ulcerative colitis","volume":"47","author":"Husain","year":"2013","journal-title":"Journal of Clinical Gastroenterology"},{"key":"10.1016\/j.dld.2016.09.001_bib0260","doi-asserted-by":"crossref","first-page":"e27321","DOI":"10.4161\/tisb.27321","article-title":"The role of Haptoglobin and its related protein, Zonulin in inflammatory bowel disease","volume":"1","author":"Vanuytsel","year":"2013","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.dld.2016.09.001_bib0265","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0171-2985(85)80080-2","article-title":"Neopterin as a new biochemical marker in the clinical assessment of ulcerative colitis","volume":"170","author":"Niederwieser","year":"1985","journal-title":"Immunobiology"},{"key":"10.1016\/j.dld.2016.09.001_bib0270","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/MIB.0b013e3182807577","article-title":"Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases","volume":"19","author":"Nancey","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2016.09.001_bib0275","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/ibd.20510","article-title":"Urinary neopterin is a valuable tool in monitoring Crohn's disease activity","volume":"14","author":"Nancey","year":"2008","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2016.09.001_bib0280","first-page":"22","article-title":"Mononuclear cell activation in Crohn's disease: evaluation using serum assay of neopterin and interleukin-2 soluble receptors","volume":"14","author":"Duclos","year":"1990","journal-title":"Gastroenterologie Clinique et Biologique"},{"key":"10.1016\/j.dld.2016.09.001_bib0285","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0009-8981(86)90094-X","article-title":"Urinary neopterin, a marker of clinical activity in patients with Crohn's disease","volume":"155","author":"Prior","year":"1986","journal-title":"Clinica Chimica Acta"},{"key":"10.1016\/j.dld.2016.09.001_bib0290","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1152\/physrev.00003.2008","article-title":"Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer","volume":"91","author":"Fasano","year":"2011","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.dld.2016.09.001_bib0295","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.3748\/wjg.14.5584","article-title":"Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease","volume":"14","author":"Wagner","year":"2008","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2016.09.001_bib0300","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1097\/MIB.0000000000000087","article-title":"Fecal biomarkers in the diagnosis and monitoring of Crohn's disease","volume":"20","author":"Wright","year":"2014","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2016.09.001_bib0305","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/ibd.20490","article-title":"Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease","volume":"14","author":"Sipponen","year":"2008","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2016.09.001_bib0310","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00384-006-0159-9","article-title":"Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease","volume":"22","author":"D\u2019Inc\u00e0","year":"2007","journal-title":"International Journal of Colorectal Disease"},{"key":"10.1016\/j.dld.2016.09.001_bib0315","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/ibd.20933","article-title":"Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse","volume":"15","author":"Gisbert","year":"2009","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2016.09.001_bib0320","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1016\/j.crohns.2013.08.005","article-title":"Is fecal calprotectin useful for monitoring endoscopic disease activity in patients with postoperative Crohn's disease?","volume":"7","author":"Yamamoto","year":"2013","journal-title":"Journal of Crohn's and Colitis"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865816307307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865816307307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T08:52:10Z","timestamp":1536396730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865816307307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1590865816307307"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2016.09.001","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2016.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}